Italy: no appetite for “self-help” policies

Italy's huge public debt pile and high financing needs mean it could use some deep-pocketed investors, but its insistence on a budget that might break EU rules doesn’t make it attractive.

911_MW_P06_Markets_Main

Italy: the eurozone's Achilles' heel

"Italy's on the ropes," says Marcus Ashworth on Bloomberg. Its huge public debt pile, worth around 130% of GDP, and high consequent financing needs, mean its bond market could use some "deep-pocketed patrons". However, Italy's insistence on a budget that might break EU rules on deficit limits doesn't make it particularly attractive. Italy's government has called for a "budget-busting package", which includes "a flat tax for the right and universal income for the left". That would swell the deficit to 7% of GDP, way past the 3% permitted under the rules of the euro, says Randall Forsyth on Barron's.

A timely offer

Enter Donald Trump, who has reportedly offered to buy some of Italy's sovereign bonds next year. This timeframe would coincide with the end of the European Central Bank's bond purchasing through quantitative easing, which has been a major boon to government bonds across the eurozone.

Buying bonds with printed money has kept long-term interest rates countries' borrowing costs down, especially in the case of the southern states that faced rising bond yields during the bloc's debt crisis, as Adam Samson notes in the Financial Times. Furthermore, in recent weeks there have been signs that investors are beginning to get fed up with the new populist government's antics. The Italian ten-year bond yield has climbed to over 3%, from 2% at the start of the year, showing that bond prices have fallen. Yields on the Italian ten-year bond are nearly 3% higher than Germany's. Foreign investors sold a record €38bn ($43.9bn) in Italian debt in June, up from €34bn in May, according to ECB data.

that will come to nothing

Any real effort by Trump to follow through on his offer would encounter domestic resistance, so American purchases of Italian debt are unlikely. But the way things are going, Italy is heading for another debt crisis when the safety net of ECB bond buying is removed next year.

A bond-market crash isn't inevitable, says Neil Unmack on Breakingviews. If Italy can do more to boost its economic growth and bring down its debt, both investors and Brussels might be more tolerant. It could, for example, sell assets such as real estate or make the country more business friendly, suggests Unmack. "Self-help is Italy's best backstop."

Unfortunately, however, all the evidence so far suggests this could be a stretch. The last few governments made scant progress on structural reforms to bolster Italy's long-term growth rate. The latest one has gone backwards, "unpicking" minor pension and labour reforms. As a result, estimates Barclays, its potential growth rate will fall by 0.3%, which is pretty grim given that it is currently only 1%. Another item on the towering to-do list is to trim corporation tax to encourage entrepreneurship. Given all these structural problems, and no interest in addressing them, it's no wonder investors are worried that Italy is the eurozone's Achilles' heel.

Recommended

How the Covid-19 vaccine crisis is putting the EU in danger
EU Economy

How the Covid-19 vaccine crisis is putting the EU in danger

The botched coronavirus vaccine campaign will cause long-term harm to the EU's economy, says Matthew Lynn.
4 Apr 2021
How the vaccine wars will harm us all
Global Economy

How the vaccine wars will harm us all

Grabbing and hoarding vaccine supplies, or even manufacturing one’s own, might seem to make sense for a state in an emergency. But the damage done to …
27 Mar 2021
The European Central Bank fumbles its way towards yield curve control
EU Economy

The European Central Bank fumbles its way towards yield curve control

The EU’s economic recovery is faltering, but its bond yields keep rising. That makes things tricky for the European Central Bank, says John Stepek. He…
12 Mar 2021
Vexing vaccine delays hit drug firms
Biotech stocks

Vexing vaccine delays hit drug firms

AstraZeneca and Pfizer are being attacked by the EU over what it claims are delays in delivering the Covid vaccine.
28 Jan 2021

Most Popular

Central banks are rushing to build digital currencies. What are they, and what do they mean for you?
Bitcoin

Central banks are rushing to build digital currencies. What are they, and what do they mean for you?

As bitcoin continues to soar in value, many of the world’s central banks are looking to emulate it by issuing their own digital currencies. But centra…
8 Apr 2021
Nuclear power might never be popular – but now looks a good time to invest
Commodities

Nuclear power might never be popular – but now looks a good time to invest

Nuclear power gets a very bad press, but it is the ultimate renewable energy source. Interest in it is perking up again, says John Stepek. Which means…
9 Apr 2021
House prices: from boom to even bigger boom
House prices

House prices: from boom to even bigger boom

UK house prices have risen to new to record highs, says Nicole Garcia Merida. Demand continues to outpace supply, but continued low interest rates, th…
9 Apr 2021